Merck KGaA (VIE:MRCK)
Austria · Delayed Price · Currency is EUR | Market Cap | 47.74B -16.4% |
| Revenue (ttm) | 21.10B -0.3% |
| Net Income | 2.61B -6.1% |
| EPS | 6.00 -6.1% |
| Shares Out | n/a |
| PE Ratio | 18.30 |
| Forward PE | 14.13 |
| Dividend | 2.20 (2.05%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | n/a |
| Average Volume | 5 |
| Open | 108.65 |
| Previous Close | 110.20 |
| Day's Range | 107.35 - 109.20 |
| 52-Week Range | 100.60 - 131.45 |
| Beta | n/a |
| RSI | 44.84 |
| Earnings Date | May 13, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Financial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial StatementsNews
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings
The company anticipates currency headwinds would continue to weigh on its earnings this year, as the life-sciences and chemical company prepares for a leadership change.
Merck KGaA sees earnings decline of up to 4%
Germany's Merck KGaA said on Thursday it expects 2026 adjusted operating profit to slip by up to 4%, excluding currency effects.
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially worth over $3 billio...
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson's Disease and Related Disorders
LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson's and related disorders.
Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units
Merck KGaA's sales grew 5.2%, driven by demand for pharma-production products, rare diseases treatments and semiconductor materials in its electronics unit.
Merck KGaA's Q3 profit rises, beats market view
Merck KGaA reported on Thursday a slight gain in quarterly operating earnings that beat market expectations, benefiting from legislative changes in South America and the sale of a priority review vouc...
Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.
President Donald Trump on Thursday announced a deal with EMD Serono, a subsidiary of German drugmaker Merck KGaA, that aims to cut the out-of-pocket costs for in vitro fertilization, with the move com...
Trump announces efforts to expand access to IVF drugs
President Donald Trump announced two new efforts to expand availability of in vitro fertilization, the first concrete step from the Trump administration on the expensive, decades-old procedure. It inc...
Trump Announces Deal With Germany's Merck on IVF Costs
President Donald Trump announces a deal with Germany's Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs. He speaks during a a press confere...
Germany's Merck Sets Out Midterm Sales Growth, Profitability Expansion Targets
The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.
Germany's Merck tweaks mid-term healthcare unit guidance
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Chinese police investigating app fraud case, says German drugmaker Merck KGaA
Police in China are investigating an app fraud case, said German healthcare firm Merck KGaA , amid growing concerns over entities claiming affiliation with major corporations.
Merck and Siemens Deepen Strategic Partnership to Accelerate AI and Data-Driven Drug Discovery and Development
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, and Siemens, a leading technology company, signed a new Memorandum of Understanding (MoU), extending their strateg...
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drug...
Merck KGaA, Darmstadt, Germany, Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Ch...
Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has closed the acquisition of SpringWorks Therapeutics, Inc., for...
China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical P...
China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (N...
Merck KGaA Cuts Outlook Amid Macroeconomic Challenges
The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic conditions and foreign-exchange headwinds.
Merck KGaA strikes more cautious tone on 2025 adj profit
Germany's Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing the macro-economic and geopolitical environment as well as foreign-exchange headwinds.
Germany's Merck drops China surcharge on orders after US-China tariff deal
German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China following the U.S.-China agreement to pause sky-high tariffs on each other, the com...
Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal
The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.
Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks
German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug busi...